GlobeNewswire

Incap Corporation: THE BOARD OF DIRECTORS OF INCAP HAS RESOLVED ON PAYING A PART OF THE PURCHASE PRICE PAYABLE TO THE SELLERS OF AWS ELECTRONICS GROUP IN NEW SHARES OF INCAP CORPORATION

Share

INCAP CORPORATION

STOCK EXCHANGE RELEASE 26 February 2021 at 5.30 p.m. (EET)


THE PURCHASE OF AWS ELECTRONICS GROUP

Incap Corporation (the  “Company” or  “Incap”) announced on 23 January 2020 that it has signed an agreement to acquire the entire share capital of AWS Electronics Group (“AWS”). The group has been included in Incap Group’s reporting as of 23 January 2020.

The debt-free purchase price was 13.5 million pounds (then approximately EUR 15.9 million), and the additional purchase price amounted to EUR 0.6 million. The acquisition was financed with a loan of EUR 13 million and paid in cash, with the exception of an instalment of 0.6 million pounds to be paid in Incap shares.

A PART OF THE PURCHASE PRICE

The Board of Directors of the Company has on 26 February 2021 resolved, that the sellers of AWS will be paid an equivalent of 600,000 pounds in new shares of the Company in a directed share issue with payment (the “Share Issue”). The Share Issue will be consummated on 26 February 2021, by offering a total of 29,103 new shares in the Company to be subscribed by the sellers of AWS. In the Share Issue, the subscription price of one new Incap share is EUR 23.86 and the total subscription price of the Share Issue is thus EUR 694,380 (600,000 pounds). The subscription price per share is based on the acquisition agreement of AWS’ shares and corresponds to the average closing Bid and Ask price levels of Incap’s share at the end each transaction date on Nasdaq Helsinki during the period  19 – 25 February 2021.

The total subscription price of the Share Issue shall be recorded in its entirety to the reserve for invested unrestricted equity of the Company.

The acquisition of AWS was and is still aligned with the Company’s strategy and as the Share Issue relates to the payment of a part of the purchase price agreed earlier, therefore the Company has a weighty financial reason to deviate in the Share Issue from the Company’s shareholders’ pre-emptive subscription right, in accordance with Chapter 9, Section 4, Subsection 1 of the Finnish Limited Liability Companies Act (624/2006, as amended).

The Board of Directors of the Company decided on the Share Issue based on the authorization granted to it by the Annual General Meeting of 20 April 2020.The number of Incap shares will increase from 5,820,224 shares to 5,849,327 shares after the registration of the new shares. The new shares of the Company will be applied for trading together with the other shares of the Company on Nasdaq Helsinki approximately by 31 March 2021.

INCAP CORPORATION


Further information:

Otto Pukk, CEO, +372 508 0798


DISTRIBUTION

Nasdaq Helsinki Ltd.

Principal media

www.incapcorp.com


INCAP IN BRIEF

Incap Corporation is a trusted partner and full service provider in Electronics Manufacturing Services. As a global EMS company Incap supports customers ranging from large multinationals and mid-sized companies to small start-ups in their complete manufacturing value chain. Incap offers state-of-the-art technology backed up by an entrepreneurial culture and highly qualified personnel. The company has operations in Finland, Estonia, India, Slovakia, the UK and Hong Kong and employs approximately 1,900 people. Incap’s share has been listed on Nasdaq Helsinki Ltd stock exchange since 1997.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million23.4.2021 07:00:00 CEST | Press release

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million Schiphol, the Netherlands – 23 April 2021. GrandVision N.V. publishes its First Quarter 2021 trading update. Due to the exceptional nature of the year 2020, GrandVision will also include in the present press release comparisons versus 2019. Highlights • GrandVision continues to show resilience in the first quarter despite the most recent COVID-19 related government restrictions in Europe and Latam • At constant exchange rates, revenue declined by -0.7% compared with 1Q20 to €899 million from €926 million in 1Q20 (1Q19: €974m) • Comparable revenue declined by -1.5% versus 1Q20 and on a 2019 basis, -10.8% versus 1Q19 • Adj. EBITA increased by 98.1% at constant exchange rates to €79 million from €41 million in 1Q20 (1Q19: €107m). Continued cost discipline, structural improvements in certain territories and improved product and price mix contributed to the underlying performance • Adj. EBITA margin at 8.8%,

Corbion appoints Aurélie Dalbiez as Chief Human Resources Officer23.4.2021 07:00:00 CEST | Press release

Corbion announces the appointment of Aurélie Dalbiez as Chief Human Resources Officer and member of the Executive Committee as of 1 July 2021. Mrs. Dalbiez (a French national) currently is Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career at Deutsche Bank before working for Capital International, a global investment company. CEO Olivier Rigaud commented: "I am really pleased to welcome Aurélie to the ExCo team as a seasoned HR leader who partners closely with the business to develop talent, drive culture, engagement, continuous improvement, and customer intimacy. Her appointment will also further enhance the diversity of our ExCo." Mrs. Dalbiez brings a multi-cultural background and perspective. She lived in the United States as a child, earned her university degree in International Business in Lyon, France and worked internationally throughout

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy23.4.2021 07:00:00 CEST | Press release

About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. Endometrial cancer is the most common gynecologic can

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies23.4.2021 06:01:00 CEST | Press release

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium;23April 2021;06.01 CET; –Galapagos NV (Euronext & Nasdaq: GLPG) today report that their collaboration partnerGilead Sciences K.K. (“Gilead”) and Eisai Co., Ltd. (“Eisai”)today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis (UC).Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis. This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study evaluating the efficacy and safety of filgotinib for the induction and maintenance of remission in patients with moderately to severely active ulcerative colitis who have had a

Camposol Holding PLC Invitation to the Presentation of Fourth Quarter and Audited Full Year 2020 Financial Results23.4.2021 02:00:00 CEST | Press release

Camposol Holding PLC will announce the results for the full year 2020 on Thursday, April 29, 2021. In connection with the release, a telephone conference will be held at 9:30 a.m. (Lima) as described below. The presentation will be published at 8:30 a.m. (Lima) and will be available on the Company's website. In connection with the earnings release Samuel Dyer Coriat, CEO, and Andrés Colichón Sas, CFO, will host a conference call presentation and a Q&A session at 9:30 a.m. (Lima). To participate in the conference call, please use the following numbers: London, UK Local +0800 028 8438 US/Canada International +1 409 981 0728 Zurich, Switzerland, Local +044 580 1740 Oslo, Norway, Local +47 8001 6162 Colombia, National Free Phone +01 800 518 5094 Chile, National Free Phone +56 800 914 686 Peru, National Free Phone +51 0800 71470 Participants will be asked for their name and conference ID. The Camposol conference ID is: 2466977 Audio access for the meeting is available by dialing the above-m

CrossAmerica Partners LP Maintains Quarterly Distribution22.4.2021 22:30:00 CEST | Press release

•Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 Allentown, PA, April 22, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the firstquarter of 2021 ALLENTOWN, PA (April 22, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 11, 2021 to all unitholders of record on May 4, 2021. CrossAmerica will host a conference call on May 11th at 9:00 a.m. Eastern Time to discuss first quarter earnings results, which will be released after the market closes on Monday, May 10. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and